Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
9 May 24
ARS
2023 FY
Annual report to shareholders
2 May 24
DEFA14A
Additional proxy soliciting materials
2 May 24
DEF 14A
Definitive proxy
2 May 24
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
27 Mar 24
S-3
Shelf registration
21 Mar 24
424B3
Prospectus supplement
20 Mar 24
8-K
Material Modifications to Rights of Security Holders
20 Mar 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18 Mar 24
S-3
Shelf registration
4 Mar 24
D
$127.80 mm in equity / options, sold $127.80 mm, 20 investors
21 Feb 24
8-K
Regulation FD Disclosure
8 Feb 24
8-K
In the Court of Chancery of the State of Delaware
6 Feb 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
UPLOAD
Letter from SEC
25 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
UPLOAD
Letter from SEC
18 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
8-K/A
Departure of Directors or Certain Officers
4 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Departure of Directors or Certain Officers
4 Aug 23
8-K
Other Events
14 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Departure of Directors or Certain Officers
25 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 May 23
8-K
Other Events
11 May 23
424B5
Prospectus supplement for primary offering
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
11 May 23
EFFECT
Notice of effectiveness
3 May 23
UPLOAD
Letter from SEC
1 May 23
CORRESP
Correspondence with SEC
28 Apr 23
Latest ownership filings
SC 13G/A
BML Investment Partners, L.P.
29 Apr 24
4
Setareh Seyedkazemi
12 Mar 24
4
Peter Soparkar
12 Mar 24
4
Laurent Fischer
12 Mar 24
SC 13G
Logos Global Management LP
22 Feb 24
SC 13G
TCG Crossover GP II, LLC
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
4
Setareh Seyedkazemi
14 Feb 24
4
Laurent Fischer
14 Feb 24
SC 13G
Vivo Opportunity Fund Holdings, L.P.
14 Feb 24
4
Linda M Rubinstein
14 Feb 24
4
Peter Soparkar
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
MORGAN STANLEY
12 Feb 24
4
James Paul Scopa
9 Feb 24
4
Jr. Mark L. Lupher,
9 Feb 24
SC 13G
Frazier Life Sciences Public Fund, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
C. David Nicholson,
6 Nov 23
3
C. David Nicholson,
6 Nov 23
4
Setareh Seyedkazemi
18 Sep 23
4
Linda M Rubinstein
5 Sep 23
SC 13G
Venrock Healthcare Capital Partners III, L.P.
24 Jul 23
4
Rabia Gurses Ozden
13 Jun 23
4
James Paul Scopa
13 Jun 23
4
Scott M Whitcup
13 Jun 23
4
Reed Vaughn Tuckson
13 Jun 23
4
Dawn Svoronos
13 Jun 23
4
Jr. Mark L. Lupher,
13 Jun 23
4
Soo Hong
13 Jun 23
4
Patrick Machado
13 Jun 23
4
Linda M Rubinstein
9 Jun 23
SC 13G
COMMODORE CAPITAL LP
20 Apr 23
4
Brigit Riley
17 Mar 23
4
Peter Soparkar
17 Mar 23
4
Laurent Fischer
17 Mar 23
4
Brigit Riley
3 Mar 23
4
Setareh Seyedkazemi
3 Mar 23